BTX161
- CAS No.
- 2052301-24-1
- Chemical Name:
- BTX161
- Synonyms
- BTX161;(S)-3-(4-Methyl-1-oxoisoindolin-2-yl)azepane-2,7-dione;1H-Azepine-2,7-dione, 3-(1,3-dihydro-4-methyl-1-oxo-2H-isoindol-2-yl)tetrahydro-, (3S)-
- CBNumber:
- CB84667698
- Molecular Formula:
- C15H16N2O3
- Molecular Weight:
- 272.3
- MDL Number:
- MFCD34578207
- MOL File:
- 2052301-24-1.mol
- MSDS File:
- SDS
- TDS File:
- TDS
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319 |
| Precautionary statements | P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330 |
BTX161 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0069459 | BTX161 99.20% | 2052301-24-1 | 5mg | $412 | 2026-06-04 | Buy |
| ChemScene | CS-0069459 | BTX161 99.20% | 2052301-24-1 | 10mg | $650 | 2026-06-04 | Buy |
| ChemScene | CS-0069459 | BTX161 99.20% | 2052301-24-1 | 25mg | $1246 | 2026-06-04 | Buy |
| ChemScene | CS-0069459 | BTX161 99.20% | 2052301-24-1 | 50mg | $1950 | 2026-06-04 | Buy |
| ChemScene | CS-0069459 | BTX161 99.20% | 2052301-24-1 | 100mg | $3087 | 2026-06-04 | Buy |
BTX161 Chemical Properties, Uses, Production
Uses
BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.
Biological Activity
BTX161, a Thalidomide analog, is a potent CKIα degrader. BTX161 mediates degradation of CKIα better than Lenalidomide in human AML cells and activates DNA damage response (DDR) and p53, while stabilizing the p53 antagonist MDM2[1]. BTX161 (25 μM; 4 hours; MV4-11 cells) upregulates all the Wnt targets including MYC and did not affect MDM2 mRNA expression[1].BTX161 (10 μM; 6 hours; MV4-11 cells), on its own, augmented p53 and MDM2 protein expression, yet in combination with THZ1, and particularly with both THZ1 and CDK9, further augmented p53 and induced maximal caspase 3 activation[1].
References
[1]. Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018;175(1):171-185.e25.
BTX161 Preparation Products And Raw materials
Raw materials
Preparation Products
BTX161 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd | 15317229551 | 15151849396@163.com | China | 975 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 13681763483 | product02@bidepharm.com | China | 59929 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Nanjing Shizhou Biology Technology Co.,Ltd | 025-85560043 15850508050 | cindy.huang@synzest.com | China | 11975 | 58 |
| SuZhou GoodChemTech Co., Ltd | 18136139868; 18136139868 | jinlun@goodchemtech.cn | China | 321 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd | 025-5885952 15955137747 | sales@aikonchem.com | China | 8012 | 58 |
| Shanghai Anbida Biotechnology Co., Ltd. | 021-61629020 18201956406 | sales@ambeed.cn | China | 7032 | 58 |
2052301-24-1 (BTX161) Related Search:
1of2
